Clinical trials: Antipsychotic Agents
Schizophrenia
A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER
The purpose of this study is to evaluate the effects of a CYP2D6 inhibitor, paroxetine, on the pharmacokinetics of a single dose of orally administered paliperidone ER and to evaluate the safety and tolerability of both…
- Trial name
- NCT00791713
- Testing
- Paliperidone ER
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
The purpose of this study is to explore the efficacy of paliperidone palmitate administered as a once monthly injection in patients with an acute exacerbation of schizophrenia.
- Trial name
- NCT01448720
- Testing
- Paliperidone palmitate
- Where
- 12 sites in Brazil, Colombia and 1 more
- Volunteers
- 142 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Schizophrenia, Schizoaffective Disorder
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
Weight gain is a serious, common side effect of many antipsychotic medications. On average, the highest amounts of weight gain are found to occur in people taking clozaril and olanzapine, but with significant weight gain occuring…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders
- Trial name
- NCT00312598
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
This study is designed to compare the efficacy and drug tolerability of two strategies for the treatment of schizophrenia. The two strategies consist of utilizing, on the one hand, a conventional antipsychotic like haloperidol or…
- Trial name
- NeSSy (NCT01164059)
- Testing
- Olanzapine, Flupentixol, Quetiapine
- Where
- 18 sites in Germany
- Volunteers
- 149 people
- Sponsor
- University of Bremen
Schizophrenia With Impulsivity
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
The purpose of this study is to evaluate the effect of brexpiprazole, via functional magnetic resonance imaging (fMRI), on the right ventrolateral prefrontal cortex (VLPFC) activated by impulsive behavior.
- Trial name
- NCT02194933
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Weight Gain
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
Lifestyle intervention and certain medications have been shown to be effective for antipsychotic-induced weight gain, but no controlled studies have compared psychological and pharmacological therapies.
- Trial name
- NCT00451399
- Testing
- metformin, lifestyle intervention
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Central South University
Schizophrenia, Schizoaffective Disorder
Naltrexone for Antipsychotic-Induced Weight Gain
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NTX (NCT01866098)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Schizophrenia
Predicting Antipsychotic Discontinuation in Psychosis
The purpose of this study is to determine whether dopamine synthesis capacity by using [18 fluorine(F)]-DOPA PET for patients with schizophrenia in the maintenance phase can predict treatment discontinuation.
- Trial name
- PADP (NCT02884518)
- Testing
- PET, clinical scale
- Where
- South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
SSRI-Refractory Obsessive-Compulsive Disorder
Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant obsessive-compulsive disorder (OCD) in short terms trials…
- Trial name
- OCDDRUG (NCT00854919)
- Testing
- atypical antipsychotic drug, exposure response prevention
- Where
- Japan
- Sponsor
- Osaka City University
Schizophrenia
Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects
This study will examine possible causes of metabolic side effects in people taking atypical antipsychotic (AAP) medications.
- Trial name
- NCT00815854
- Testing
- Folic Acid
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Michigan
Schizophrenia
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability.
- Trial name
- NCT02013622
- Testing
- Brexpiprazole
- Where
- 22 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Extrapyramidal Symptoms, Drug-induced Parkinsonism
A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms
This prospective, single-center observational study aims to develop and validate a computer-assisted tool for the objective quantitative assessment of extrapyramidal symptoms (EPS).
- Conditions
- Extrapyramidal Symptoms, Drug-induced Parkinsonism, Akathisia, Drug-Induced, Tardive Dyskinesia (TD)
- Trial name
- NCT07715994
- Testing
- Computer-Assisted Objective Assessment of Extrapyramidal Symptoms
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics
International Observational Registry on Schizophrenia
- Trial name
- NCT01026285
- Testing
- Risperidone Long-Acting injectable or oral antipsychotics
- Where
- 98 sites in Czechia, France and 6 more
- Volunteers
- 1,085 people
- Sponsor
- Janssen-Cilag International NV
Eating Disorders
Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
This study will evaluate the effectiveness of the antipsychotic medication olanzapine in treating outpatients with anorexia nervosa.
- Trial name
- NCT00692185
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
This is a randomized, double-blind, placebo-controlled, sequential cohort, ascending oral dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of EVP-6308 administered for 14 days in subjects with…
- Trial name
- NCT02037074
- Testing
- Drug: EVP-6308
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- FORUM Pharmaceuticals Inc
Emergency Psychiatric, Cognition Disorder
DIAMOND-Lewy Guidelines for Antipsychotic Use in Older Patients
The goal of this observational study is to learn about current practices for the acute neuropsychiatric management of older adults during emergency department (ED) visits.
- Conditions
- Emergency Psychiatric, Cognition Disorder, Movement Disorders, Antipsychotics and Neuroleptics Toxicity
- Trial name
- NCT06357195
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Ohio State University
Scizophrenia
Carbergoline for Antipsychotic Induced Hyperprolactinemia.
The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia.
- Trial name
- NCT07386080
- Testing
- Cabergoline (Dopamine Agonist)
- Where
- Denmark
- Volunteers
- 146 people
- Sponsor
- Zealand University Hospital
Schizophrenia
Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia
Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve Cognitive function in Schizophrenia
- Trial name
- TAAS (NCT02040883)
- Testing
- Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole, Tandospirone
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qingyun Yin
Schizophrenia
The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia
This is a 12-month open-label randomized controlled study. Patients with schizophrenia and violence risk under the government supervision will be enrolled in the study.
- Trial name
- NCT03080194
- Testing
- paliperidone palmitate, control group
- Volunteers
- 150 people
- Sponsor
- Maosheng Fang